A

Amgen

Makes biotech medicines for serious illnesses

Process Development Senior Scientist

Full-TimeUpdated on 10/24/2026
$126.1k - $170.6k+ Annual bonus + Stock-based long-term incentives
Senior
Bachelor's, Master's, PharmD, PhD, MD
Thousand Oaks, CA, USA
In PersonOn-site in Thousand Oaks, California.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A doctorate degree (PhD, PharmD, or MD), with relevant postdoctoral experience where applicable; or a master's degree and 3 years of scientific experience; or a bachelor's degree and 5 years of scientific experience.
  • A doctorate degree with 5 years of experience in Analytical Chemistry, Biochemistry, or equivalent is preferred.
  • Relevant experience working as part of a multidisciplinary team in a biopharmaceutical setting is preferred.
  • A strong background in analytical method development of biologics such as monoclonal antibodies and multispecifics is preferred.
  • Proficiency in mass spectrometry techniques, including intact mass and peptide mapping assays for characterizing biologic therapeutics, is preferred.
  • Proficiency in other HPLC and CE methods such as reversed-phase HPLC, size-exclusion HPLC, ion-exchange HPLC, affinity HPLC, CE-SDS, and cIEF for biologics is preferred.
  • Knowledge of regulatory requirements and guidelines and prior experience authoring or contributing to regulatory filings is preferred.
  • Familiarity with commonly observed product quality attributes associated with therapeutic proteins, such as glycosylation, deamidation, oxidation, and partial reduction, and their characterization and quantification tools is preferred.
  • Ability to develop, validate, transfer, and remediate methods for in-process, release, and stability testing is preferred.
  • A solid understanding of Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) requirements and their application in a phase-appropriate manner is preferred.
  • Experience in technical transfer for non-GMP and GMP production and testing to external contract organizations, managing deliverables against timelines, is preferred.
  • Ability to provide cross-functional leadership and guidance to Chemistry, Manufacturing, and Controls (CMC) and non-clinical teams, such as informing and defending the Quality Target Product Profile, is preferred.
  • Experience working in cross-functional teams and across geographic locations in different time zones is preferred.
  • Technical writing skills and attention to detail in authoring methods, specifications, technical reports, and regulatory filing documents are preferred.
  • Experience with protein-based and live modality therapies, including monoclonal antibodies, bi/tri-specific antibodies, fusion proteins, and gene therapy, is beneficial.
  • Strong problem-solving, multifunctional interpersonal, communication, leadership, and decision-making skills are preferred.
Responsibilities
  • Supervise and provide technical support for a team that provides analytical support for late-stage product development.
  • Act as an Attribute Sciences team lead for a program in pivotal clinical process development and be responsible for all analytical work supporting the program.
  • Define the analytical target profile (ATP) for methods used to monitor product quality and oversee the development, qualification, remediation, and transfer of analytical methods to Quality Control based on the ATP.
  • Manage activities at contract manufacturing and testing sites.
  • Author technical reports and analytical Chemistry, Manufacturing, and Controls (CMC) sections in regulatory documents, and answer analytical and product quality questions from health authorities.
  • Drive product characterization in support of process comparability studies, regulatory filings, regulatory questions, and reference standard qualification.
  • Provide expertise and evaluate Amgen's platform and analytical technologies to help drive innovation and efficiency within Process Development.
  • Help define strategies that improve the effectiveness and efficiency of the Attribute Sciences department.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.